文献速递甲状腺核医学肿瘤 PET/CT

18F-FDG-PET/CT在不确定性甲状腺结节中的定量分类与影像组学研究

Quantitative classification and radiomics of [18F]FDG-PET/CT in indeterminate thyroid nodules.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-02-09

前瞻性纳入123例Bethesda III或IV甲状腺结节患者行18F-FDG-PET/CT,评估定量参数及影像组学对非Hürthle细胞与Hürthle细胞结节的术前鉴别能力。定量SUV指标可排除恶性,非Hürthle细胞结节在SUVmax≥2.1 g/mL等阈值下敏感性95.8%,Hürthle细胞结节需更高阈值;影像组学分析未提供额外鉴别价值。

要点

  • 非Hürthle细胞结节SUVmax截断值2.1 g/mL时排除恶性敏感性95.8%。
  • Hürthle细胞结节需更高SUV截断值(SUVmax 5.2 g/mL)才能达到100%敏感性。
  • 影像组学分析对18F-FDG阳性结节未显示额外鉴别价值(平均AUC 0.445)。

核心结论

  • 定量18F-FDG-PET/CT评估可排除不确定性甲状腺结节的恶性。
  • Hürthle细胞结节应采用更高的SUV截断值以优化排除能力。
  • 影像组学分析未对18F-FDG阳性结节的额外鉴别做出贡献。

研究设计与样本

  • 前瞻性纳入Bethesda III或IV甲状腺结节患者行18F-FDG-PET/CT显像。
  • 对标准化摄取值(SUV)及SUV比值行ROC曲线分析,评估以≥95%敏感性可靠排除恶性/交界性肿瘤的SUV截断值。
  • 对18F-FDG阳性扫描行影像组学分析:以SUVpeak的50%进行分割,从PET和低剂量CT图像提取107个影像组学特征。
  • 弹性网络回归分类器在20次重复随机拆分中训练,降维纳入拆分过程;预测性能以测试集平均AUC表示。

主要发现

  • 123例纳入患者中84例(68%)目标结节视觉18F-FDG阳性,恶性/交界性率为27%(33/123)。
  • 全部结节(n=123)SUV指标AUC为0.705(95%CI 0.601-0.810)至0.729(0.633-0.824)。
  • 非Hürthle细胞结节(n=94)SUV指标AUC为0.708(95%CI 0.580-0.835)至0.757(0.650-0.864)。
  • Hürthle细胞结节(n=29)SUV指标AUC为0.533(95%CI 0.320-0.747)至0.700(0.502-0.898)。
  • 84例(68%)18F-FDG阳性结节的影像组学分析显示PET模型测试集平均AUC为0.445(95%CI 0.290-0.600)。

关键数值与推荐

  • 非Hürthle细胞结节:SUVmax、SUVpeak、SUVmax比值、SUVpeak比值截断值分别为2.1 g/mL、1.6 g/mL、1.2、0.9时,18F-FDG-PET/CT敏感性为95.8%(95%CI 78.9-99.9%)。
  • Hürthle细胞结节:SUVmax、SUVpeak、SUVmax比值、SUVpeak比值截断值分别为5.2 g/mL、4.7 g/mL、3.4、2.8时,敏感性为100%(95%CI 66.4-100%)。

临床怎么用

  • 定量18F-FDG-PET/CT评估可用于排除不确定性甲状腺结节的恶性。
  • Hürthle细胞结节应使用更高的SUV截断值以优化排除能力。
  • 影像组学分析未对18F-FDG阳性结节提供额外鉴别价值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate whether quantitative [18F]FDG-PET/CT assessment, including radiomic analysis of [18F]FDG-positive thyroid nodules, improved the preoperative differentiation of indeterminate thyroid nodules of non-Hürthle cell and Hürthle cell cytology. METHODS: Prospectively included patients with a Bethesda III or IV thyroid nodule underwent [18F]FDG-PET/CT imaging. Receiver operating characteristic (ROC) curve analysis was performed for standardised uptake values (SUV) and SUV-ratios, including assessment of SUV cut-offs at which a malignant/borderline neoplasm was reliably ruled out (≥ 95% sensitivity). [18F]FDG-positive scans were included in radiomic analysis. After segmentation at 50% of SUVpeak, 107 radiomic features were extracted from [18F]FDG-PET and low-dose CT images. Elastic net regression classifiers were trained in a 20-times repeated random split. Dimensionality reduction was incorporated into the splits. Predictive performance of radiomics was presented as mean area under the ROC curve (AUC) across the test sets. RESULTS: Of 123 included patients, 84 (68%) index nodules were visually [18F]FDG-positive. The malignant/borderline rate was 27% (33/123). SUV-metrices showed AUCs ranging from 0.705 (95% CI, 0.601-0.810) to 0.729 (0.633-0.824), 0.708 (0.580-0.835) to 0.757 (0.650-0.864), and 0.533 (0.320-0.747) to 0.700 (0.502-0.898) in all (n = 123), non-Hürthle (n = 94), and Hürthle cell (n = 29) nodules, respectively. At SUVmax, SUVpeak, SUVmax-ratio, and SUVpeak-ratio cut-offs of 2.1 g/mL, 1.6 g/mL, 1.2, and 0.9, respectively, sensitivity of [18F]FDG-PET/CT was 95.8% (95% CI, 78.9-99.9%) in non-Hürthle cell nodules. In Hürthle cell nodules, cut-offs of 5.2 g/mL, 4.7 g/mL, 3.4, and 2.8, respectively, resulted in 100% sensitivity (95% CI, 66.4-100%). Radiomic analysis of 84 (68%) [18F]FDG-positive nodules showed a mean test set AUC of 0.445 (95% CI, 0.290-0.600) for the PET model. CONCLUSION: Quantitative [18F]FDG-PET/CT assessment ruled out malignancy in indeterminate thyroid nodules. Distinctive, higher SUV cut-offs should be applied in Hürthle cell nodules to optimize rule-out ability. Radiomic analysis did not contribute to the additional differentiation of [18F]FDG-positive nodules. TRIAL REGISTRATION NUMBER: This trial is registered with ClinicalTrials.gov: NCT02208544 (5 August 2014), https://clinicaltrials.gov/ct2/show/NCT02208544 .

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. de Koster EJ, Noortman WA, Mostert JM, et al. Quantitative classification and radiomics of [18F]FDG-PET/CT in indeterminate thyroid nodules. Eur J Nucl Med Mol Imaging. 2022. PMID: 35138444. doi:10.1007/s00259-022-05712-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。